{"entity":{"id":"sv-102","kind":"drug","name":"SYNC-T Therapy SV-102","aka":["SV-102","SYNC-T"],"tldr":"SYNC-T Therapy SV-102 is an experimental intratumoral multi-agent immunotherapy given with partial cryolysis from Syncromune, in phase 2 trials for metastatic castration-resistant prostate cancer.","summary":"SYNC-T Therapy SV-102 (SV-102, SYNC-T) is an intratumoral multi-agent immunotherapy given with partial cryolysis (drug-device combination) from Syncromune, with Williams Cancer Foundation as sponsor of the phase 1 trial. A small part of one tumour is frozen and thawed to release tumour antigens, then SV-102 - four immune agents: abazistobart (anti-PD-1), futermestotug (anti-CTLA-4), ciltistotug (CD40 agonist) and sitmutolimod (TLR9 agonist) - is infused into the same tumour. Its furthest stage is phase 2, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in 2 studies linked below. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Syncromune: syncromune.com","url":"https://syncromune.com/2026/10/27/syncromune-reports-long-term-data-from-phase-1-study-in-metastatic-prostate-cancer-with-investigational-sync-t-therapy-sv-102/"},{"label":"Syncromune: syncromune.com","url":"https://syncromune.com/2026/10/27/syncromune-reports-long-term-data-from-phase-1-study-in-metastatic-prostate-cancer-with-investigational-sync-t-therapy-sv-102/"},{"label":"ClinicalTrials.gov: trials of SV-102","url":"https://clinicaltrials.gov/search?intr=SV-102"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":["pd1","ctla4","cd40"],"drugs":[],"companies":["syncromune"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06533644","nct05544227"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"SV-102","modality":"Intratumoral multi-agent immunotherapy given with partial cryolysis (drug-device combination)","mechanism":"A small part of one tumour is frozen and thawed to release tumour antigens, then SV-102 - four immune agents: abazistobart (anti-PD-1), futermestotug (anti-CTLA-4), ciltistotug (CD40 agonist) and sitmutolimod (TLR9 agonist) - is infused into the same tumour.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sv-102/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"target":[{"id":"cd40","kind":"target","name":"CD40","route":"/targets/cd40/"},{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"company":[{"id":"syncromune","kind":"company","name":"Syncromune","route":"/companies/syncromune/"}],"trial":[{"id":"nct06533644","kind":"trial","name":"A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06533644/"},{"id":"nct05544227","kind":"trial","name":"Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct05544227/"}]}}